Physician profile
Anna Spelts
NPI 1679090856
$2,521.12
in general payments reported to CMS, 2019-2025
22 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $849 · 2023: $609 · 2024: $455 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $426.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $373.19 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $329.60 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $224.78 | 2022-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $188.63 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $158.52 | 2021-2024 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $109.88 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $95.01 | 2022 | |
| Amgen INC. | $86.61 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.89 | 2021-2023 | |
| Dexcom, INC. | $68.80 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $65.33 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $63.01 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $40.15 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $39.55 | 2022-2024 | Verquvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $37.16 | 2024 | |
| Sanofi-Aventis U.S. LLC | $36.61 | 2021-2022 | |
| Esperion Therapeutics, INC. | $33.78 | 2022-2023 | Nexletol |
| Daiichi Sankyo INC. | $20.89 | 2023 | Injectafer |
| Lundbeck LLC | $20.39 | 2023 | Rexulti |
| Edwards Lifesciences Corporation | $16.94 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Exact Sciences Corporation | $14.89 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Spelts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.